Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2011

Takakuwa Osamu, Oguri Tetsuya, Ozasa Hiroaki, Uemura Takehiro, Kunii Eiji, Kasai Daishi, Miyazaki Mikinori, Maeno Ken, Sato Shigeki

Abstract excerpt

INTRODUCTION: Amrubicin is a promising agent in the treatment of lung cancer, but predictive biomarkers have not yet been described. NAD(P)H:quinone oxidoreductase 1 (NQO1) is an enzyme known to metabolize amrubicinol, the active metabolite of amrubicin, to an inactive compound. We examined the relationship between NQO1 and amrubicinol cytotoxicity. METHODS: Gene and protein expression of NQO1, amrubicinol...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Carcinoma, Large Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to DNA, Neoplasm

Share to NAD(P)H Dehydrogenase (Quinone)

Share to Real-Time Polymerase Chain Reaction

Share to RNA, Small Interfering

Share to Small Cell Lung Carcinoma

Source

Identifiers

PMID: 21964527
DOI: 10.1097/JTO.0b013e318229137d

Genes

NQO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.PMID 21964527Read ↗

ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.Semantic proximity Read ↗

Clinical Significance of the NQO1 C609T Polymorphism in Non Small Cell Lung Adenocarcinoma Patients.Semantic proximity Read ↗

Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.Semantic proximity Read ↗

Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism.Semantic proximity Read ↗

NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis.Semantic proximity Read ↗

The NQO1 C609T polymorphism and risk of lung cancer: a meta-analysis.Semantic proximity Read ↗

The role of NQO1 polymorphisms in the susceptibility and chemotherapy response of Chinese NSCLC patients.Semantic proximity Read ↗

Genetic variants contributing to daunorubicin-induced cytotoxicity.Semantic proximity Read ↗

Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity.Semantic proximity Read ↗

An association between a NQO1 genetic polymorphism and risk of lung cancer.Semantic proximity Read ↗

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.Semantic proximity Read ↗

Lack of association between NADPH quinone oxidoreductase 1 (NQO1) gene C609T polymorphism and lung cancer: a case-control study and a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.